2027 ICD-10-CM Diagnosis Code C85.99Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites
ICD-10-CM Codes›C00–D49›C81-C96›C85
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 21
- Chronic Condition
C85.99 is a billable ICD-10-CM diagnosis code for Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 820 through 825, 840 through 842, 974 through 976. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 151 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Non-Hodgkin lymphoma.
For Medicare Advantage risk adjustment, C85.99 maps to CMS-HCC Category 21 (Lymphoma and Other Cancers) under the V28 model, adding a risk factor of about 0.671 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C85.99 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Diffuse non-Hodgkin's lymphoma of bone
- Diffuse non-Hodgkin's lymphoma of extranodal site
- Diffuse non-Hodgkin's lymphoma of intestine
- Diffuse non-Hodgkin's lymphoma of nasopharynx
- Diffuse non-Hodgkin's lymphoma of nose
- Diffuse non-Hodgkin's lymphoma of oral cavity
- Diffuse non-Hodgkin's lymphoma of ovary
- Diffuse non-Hodgkin's lymphoma of skin
- Diffuse non-Hodgkin's lymphoma of soft tissue
- Diffuse non-Hodgkin's lymphoma of stomach
- Diffuse non-Hodgkin's lymphoma of uterine cervix
- Encephalopathy with AIDS
- Gastric lymphoma
- Gastrointestinal lymphoma surgical margin, involved by tumor
- Lymphoma finding
- Lymphoma involves bone marrow
- Lymphoma of intestine
- Lymphoma of lower esophagus
- Lymphoma of small bowel
- Malignant lymphoma of bilateral kidneys
- Malignant lymphoma of breast
- Malignant lymphoma of esophagus
- Malignant lymphoma of extranodal AND/OR solid organ site
- Malignant lymphoma of kidney
- Malignant lymphoma of left kidney
- Malignant lymphoma of right kidney
- Malignant lymphoma of testis
- Malignant lymphoma of the eye region
- Malignant lymphoma of thyroid gland
- Malignant neoplasm of tonsil
- Malignant neoplasm with AIDS
- Malignant neoplastic disease co-occurrent with human immunodeficiency virus infection
- Metastatic malignant neoplasm to lymph nodes of lower limb
- Metastatic malignant neoplasm to lymph nodes of upper limb
- Metastatic malignant neoplasm to thyroid gland
- Non-Hodgkin lymphoma of central nervous system metastatic to lymph node of lower limb
- Non-Hodgkin lymphoma of central nervous system metastatic to lymph node of upper limb
- Non-Hodgkin's lymphoma of bone
- Non-Hodgkin's lymphoma of central nervous system
- Non-Hodgkin's lymphoma of extranodal site
- Non-Hodgkin's lymphoma of intestine
- Non-Hodgkin's lymphoma of lung
- Non-Hodgkin's lymphoma of nasopharynx
- Non-Hodgkin's lymphoma of nose
- Non-Hodgkin's lymphoma of oral cavity
- Non-Hodgkin's lymphoma of ovary
- Non-Hodgkin's lymphoma of skin
- Non-Hodgkin's lymphoma of soft tissue
- Non-Hodgkin's lymphoma of stomach
- Non-Hodgkin's lymphoma of testis
- Non-Hodgkin's lymphoma of tonsil
- Non-Hodgkin's lymphoma of uterine cervix
- Primary bone lymphoma
- Primary cerebral lymphoma
- Primary cerebral lymphoma co-occurrent with human immunodeficiency virus infection
- Primary lymphoma of brain with AIDS
- Primary oculocerebral non-Hodgkin lymphoma
- Primary pulmonary lymphoma
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C85.99: its own notes plus those printed at C85, block C81-C96, and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Lymphoma, Non-Hodgkin
any of a group of malignant tumors of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. the only common feature among these tumors is the absence of giant reed-sternberg cells, a characteristic of hodgkin's disease.
Patient EducationClinical
Lymphoma
Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C85.99 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C85.99Overview
What is the ICD-10 code for Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites?
The ICD-10-CM code for Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites is C85.99 (sometimes written as C8599). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C85.99 (Non-Hodgkin lymphoma, unspecified) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C85.99 group to?
When Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, 974, 975, 976, with relative weights from 0.7879 to 6.2454 depending on complications. Higher weights mean higher Medicare reimbursement.
Is C85.99 a CC or MCC?
CMS lists C85.99 as a CC (complication or comorbidity) for FY 2027. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 151 closely related codes in its exclusion list.
Can C85.99 be reported with a code from C86?
Not as a rule. The Excludes1 note at C85, which applies to C85.99, lists "other specified types of T/NK-cell lymphoma (C86.-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).
What HCC is C85.99?
C85.99 (Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites) maps to CMS-HCC Category 21 (Lymphoma and Other Cancers), commonly written as HCC 21, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 10 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 21.
Does C85.99 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C85.99 adds a risk adjustment factor of about 0.671 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.493 to 0.739 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, and HCC 20) supersedes it when both are reported. See the full factor table on the HCC 21 category page.
